Financial Data and Key Metrics Changes - Cash equivalents and marketable securities increased to $49.7 million as of December 31, 2025, up from $27.6 million at year-end 2024, reflecting a successful $60.3 million private placement and an upfront license payment from Chugai [12][13] - Contract revenue for Q4 2025 was $1.5 million, with total revenue for the year at $1.6 million, compared to $1 million for Q4 2024, all related to evaluation services [13][15] - Net losses for Q4 2025 were $9.1 million, down from $15.7 million in Q4 2024, while full-year net losses were $41 million compared to $56.6 million in 2024 [16][17] Business Line Data and Key Metrics Changes - Research and development expenses for Q4 2025 were $4.9 million, down from $6.8 million in Q4 2024, reflecting cost containment measures [15][16] - General and administrative expenses decreased to $5.1 million in Q4 2025 from $5.5 million in Q4 2024, primarily due to reductions in employee compensation [16] Market Data and Key Metrics Changes - The collaboration with Chugai Pharmaceutical is valued at up to approximately $1.1 billion, focusing on the development of an oral therapy using the Rani Pill platform [5][6] - The Rani Pill platform aims to replace injectable therapies with oral delivery, targeting high-value therapeutic areas such as rare diseases and immunology [6][8] Company Strategy and Development Direction - The company is focused on advancing the Rani Pill platform to enable oral delivery of biologics, with significant progress in clinical trials and strategic partnerships [4][11] - The partnership with Chugai highlights the scalability of the Rani Pill platform and the potential to apply it across various biologic molecules [6][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of the Rani Pill platform to transform biologic medicine delivery, particularly in the obesity treatment market [18] - The company is well-capitalized to execute its development plans and advance its clinical pipeline, with a projected cash runway extending into Q4 2027 [13][18] Other Important Information - The company has initiated a phase I clinical trial for RT-114, which is designed to evaluate safety, tolerability, and pharmacokinetics [10][11] - The Rani Pill platform has shown high tolerability in preclinical studies, supporting the belief that oral biologics could improve patient experience [9][11] Q&A Session Summary Question: Will weight loss data be presented for RT-114? - Management confirmed that weight loss is one of the endpoints in the phase I-B study, and they will compare it to historical data for PG-102 [20][22] Question: What additional doses will be explored for RT-114? - Management indicated that they are focused on tolerability and may consider higher doses if the data supports it, emphasizing the importance of maintaining a good tolerability profile [22][23] Question: What additional value is expected from the phase I study for RT-114? - Management highlighted that this is the first pharmacodynamics study with the Rani Pill in humans, and positive results could unlock broader applicability for the platform across various therapeutic areas [28][30]

Core Insights - Rani Therapeutics has entered a collaboration and license agreement with Chugai Pharmaceutical Co. valued at up to $1.085 billion to develop oral therapies using the RaniPill® platform [4][3] - The company has successfully completed a $60.3 million oversubscribed private placement, enhancing its financial position [4][3] - Rani Therapeutics has initiated a Phase 1 study of RT-114, a bispecific GLP-1/GLP-2 dual agonist, for obesity treatment [4][3] Financial Highlights - As of December 31, 2025, Rani Therapeutics reported cash, cash equivalents, and marketable securities totaling $49.7 million, an increase from $27.6 million in 2024 [5][11] - Contract revenue for the year ended December 31, 2025, was $1.6 million, compared to $1.0 million in 2024 [5][14] - The net loss for the year ended December 31, 2025, was $41.0 million, a decrease from $56.6 million in 2024 [5][15] Research and Development Updates - Preclinical data demonstrated successful oral delivery of semaglutide via the RaniPill® capsule, showing comparable bioavailability and weight loss to subcutaneous administration [4][3] - The bioequivalence of RT-114 delivered orally via the RaniPill® capsule to subcutaneous administration was confirmed, with a relative bioavailability of 111% [4][3] - Rani Therapeutics presented preclinical data on oral semaglutide at ObesityWeek® 2025, reinforcing the efficacy of the RaniPill® platform [4][3] Corporate Developments - The company appointed Abraham Bassan and Vasudev Bailey, Ph.D., to its Board of Directors in October 2025 [5][4] - Alireza Javadi, Ph.D., was promoted to Chief Technical Officer in January 2026 [5][4] - Rani Therapeutics has satisfied all outstanding debt obligations as of December 31, 2025, eliminating its debt burden [5][6]

Core Insights - Rani Therapeutics has appointed Jesper Høiland as Head of Strategy, who has over 30 years of experience in global pharmaceutical leadership, particularly in obesity and metabolic disease [1][3][5] Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, utilizing its proprietary RaniPill capsule technology to replace subcutaneous injections and intravenous infusions [6] Leadership Appointment - Jesper Høiland will shape Rani's corporate and pipeline strategy, prioritizing internal programs and evaluating new therapeutic opportunities, while supporting business development efforts [2][5] - Høiland's previous roles include Global Commercial Officer at Ascendis Pharma and President and CEO of Radius Health, with significant experience in launching and commercializing therapies [3][4] Strategic Focus - Høiland expressed enthusiasm for Rani's platform, highlighting the potential of oral biologics to transform treatment paradigms, particularly in the obesity space [5] - The company aims to advance its pipeline and execute long-term strategies by identifying valuable opportunities and fostering strategic partnerships [5]

Core Insights - Novo Nordisk and Vivtex Corporation have formed a partnership to develop next-generation oral biologic medicines targeting obesity, diabetes, and related comorbidities [1][6] - Vivtex will license its oral drug-delivery technologies to Novo Nordisk, which could result in Vivtex receiving up to 2.1 billion US dollars in upfront payments, research funding, and milestone payments, along with tiered royalties on future product sales [1][6] Company Overview - Novo Nordisk is a leading global healthcare company with a focus on chronic diseases, particularly diabetes, and has been innovating in protein and peptide engineering for decades [2][6] - Vivtex Corporation specializes in transforming the oral delivery of therapeutics, utilizing a robotics-driven platform that integrates high-throughput screening and AI-enabled analytics [5][6] Partnership Details - The collaboration aims to enable oral delivery of biologic drug candidates that are typically limited to injectable forms due to poor gastrointestinal absorption [2][3] - Novo Nordisk will take responsibility for global development, regulatory activities, manufacturing, and commercialization of any resulting products from this partnership [4] Technological Advancements - Vivtex's platform includes proprietary gastrointestinal screening assays and drug-delivery technologies designed to optimize the oral delivery of biologic medicines, achieving high oral bioavailability [3][5] - The partnership will leverage Vivtex's technologies to identify optimal oral formulations for peptide and protein therapeutics, enhancing their bioavailability [6]

Core Insights - Rani Therapeutics has announced a collaboration with Chugai Pharmaceutical Co. valued at up to $1.085 billion for the development of multiple high-value therapeutics [1][6] - The company completed a $60.3 million oversubscribed private placement led by Samsara BioCapital, indicating strong investor confidence [1][6] - Rani Therapeutics appointed two new members, Abraham Bassan and Vasudev Bailey, Ph.D., to its Board of Directors, enhancing its leadership team [1][6] - The company's cash runway is expected to extend into 2028, providing a solid financial foundation for future operations [1][10] Collaboration and Financial Highlights - The collaboration with Chugai includes an option for Chugai to expand its rights to up to five additional drug targets, potentially increasing the total deal value [6] - The private placement involved institutional investors and included the conversion of $6.0 million of outstanding debt, reducing the company's total debt obligations [6][10] - Rani Therapeutics presented preclinical data on semaglutide delivered orally via the RaniPill® at ObesityWeek® 2025, showcasing the platform's effectiveness [6] Upcoming Milestones - The company plans to initiate a Phase 1 clinical trial for RT-114, a novel oral therapy targeting obesity, by the end of 2025 [4][2] - The upcoming trial will assess safety, tolerability, and pharmacokinetics, which are critical for future development phases [4] Financial Performance - For Q3 2025, Rani Therapeutics reported a net loss of $7.9 million, a decrease from $12.7 million in Q3 2024, reflecting improved financial management [10][14] - Research and development expenses for Q3 2025 were $3.2 million, down from $6.2 million in the same period last year, indicating cost control measures [10][14] - General and administrative expenses also decreased to $4.0 million from $5.6 million year-over-year, further demonstrating financial discipline [10][14]

Core Insights - Rani Therapeutics has entered into a collaboration and license agreement with Chugai Pharmaceutical for the development of an oral product utilizing Rani's RaniPill technology and Chugai's antibody for rare diseases [1][2] - The total potential deal value could exceed $1 billion if Chugai exercises options for additional drug targets [1][2] Financial Details - Rani will receive an upfront payment of $10 million and is eligible for up to $75 million in technology transfer and development milestones, as well as up to $100 million in sales milestones [1][2] - A private placement financing led by Samsara BioCapital is expected to yield approximately $60.3 million, which, along with other expected proceeds, will fund Rani's operations into 2028 [4] Strategic Importance - The partnership aims to combine Rani's oral delivery technology with Chugai's expertise in complex antibodies, addressing the need for less burdensome oral therapies for patients with high unmet medical needs [2][3] - Rani's technology is expected to transform the administration of biologics, traditionally limited to injections, thereby enhancing patient quality of life [3][7]

Core Insights - Rani Therapeutics has entered into a research agreement with Chugai Pharmaceutical to evaluate the feasibility of applying Rani's oral delivery technology to Chugai's antibodies against undisclosed targets [1][2] - The RaniPill delivery system has demonstrated comparable bioavailability to subcutaneous delivery for the studied molecules [1] - Rani Therapeutics has evaluated 19 diverse molecules preclinically and completed three Phase 1 clinical trials with the RaniPill capsule, showcasing its broad applicability across various biologics [2] Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company focused on developing technologies for orally administered biologics and drugs, specifically through its proprietary RaniPill capsule [3] - The RaniPill capsule aims to replace subcutaneous injections or intravenous infusions with oral dosing, having successfully conducted several preclinical and clinical studies to evaluate its safety, tolerability, and bioavailability [3] Chugai Pharmaceutical Overview - Chugai Pharmaceutical, headquartered in Tokyo, is a research-based pharmaceutical company known for its drug discovery capabilities, including proprietary antibody engineering technologies [4] - The company is committed to creating innovative pharmaceutical products to address unmet medical needs and is a significant member of the Roche Group while maintaining its management independence [4]